





































































Standardized classification and framework for
reporting, interpreting, and analysing
medication non-adherence in cardiovascular
clinical trials: a consensus report from the
Non-adherence Academic Research
Consortium (NARC)
Marco Valgimigli1*, Hector M. Garcia-Garcia2, Bernard Vrijens3, Pascal Vranckx4,5,
Eugène P. McFadden6, Francesco Costa1,7, Karen Pieper8, David M. Vock9,
Min Zhang10, Gerrit-Anne Van Es11, Pierluigi Tricoci8, Usman Baber12,
Gabriel Steg13, Gilles Montalescot14, Dominick J. Angiolillo15, Patrick W. Serruys16,
Andrew Farb17, Stephan Windecker1, Adnan Kastrati18, Antonio Colombo19,20,
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Non-adherence has been well recognized for years to be a common issue that significantly impacts clinical outcomes and health care
costs. Medication adherence is remarkably low even in the controlled environment of clinical trials where it has potentially complex major
implications. Collection of non-adherence data diverge markedly among cardiovascular randomized trials and, even where collected, is
rarely incorporated in the statistical analysis to test the consistency of the primary endpoint(s). The imprecision introduced by the incon-
sistent assessment of non-adherence in clinical trials might confound the estimate of the calculated efficacy of the study drug. Hence, clin-
ical trials may not accurately answer the scientific question posed by regulators, who seek an accurate estimate of the true efficacy and
safety of treatment, or the question posed by payers, who want a reliable estimate of the effectiveness of treatment in the marketplace
after approval. The Non-adherence Academic Research Consortium is a collaboration among leading academic research organizations,
representatives from the U.S. Food and Drug Administration and physician-scientists from the USA and Europe. One in-person meeting
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was held in Madrid, Spain, culminating in a document describing consensus recommendations for reporting, collecting, and analysing adher-
ence endpoints across clinical trials. The adoption of these recommendations will afford robustness and consistency in the comparative
safety and effectiveness evaluation of investigational drugs from early development to post-marketing approval studies. These principles
may be useful for regulatory assessment, as well as for monitoring local and regional outcomes to guide quality improvement initiatives.
...................................................................................................................................................................................................
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Introduction
Although the mortality from cardiovascular disease (CVD) in devel-
oped economies has fallen in recent decades, CVD remains a major
worldwide cause of mortality and morbidity.1 While the reasons for
this decline are multifactorial, the advent of evidence-based pharma-
cological therapy for primary and secondary prevention has played a
significant role. However, the documented benefit of effective
pharmacological therapies is attenuated significantly by non-
adherence to prescribed therapy.2–8 The extent of the problem and
the complex nature of the phenomenon have only become apparent
in recent years.9,10
Non-adherence has been well recognized for years to be a com-
mon issue that significantly impacts clinical outcomes and health
care costs.9,10 In daily practice, medication adherence is disappointing-
ly low, especially in patients with chronic conditions, and drops
dramatically after the first 6 months of therapy.11–14 The social
consequences of non-adherence are striking: non-adherence is
associated with 125 000 deaths per year in the USA9,15 and 194 500 in
Europe16,17; the cumulative avoidable cost associated with medication
non-adherence is estimated at 310 billion dollars in the USA16 and
125 billion euros in Europe.17 Non-adherence accounts for 33% to
69% of all medication-related hospital admissions in the USA.16,18
Medication adherence is remarkably low even in the controlled
environment of clinical trials11,19–21 and has complex and potentially
major effects both on trials’ results and interpretation. These effects
reflect the interplay between the efficacy of the study medication and
the trial design (superiority vs. non-inferiority) and may be discordant
for safety and efficacy (e.g. suboptimal adherence may theoretically
blunt the efficacy but at the same time improve the safety profile of any
given antithrombotic medication). The approaches to collecting and
incorporating non-adherence data in major randomized trials diverge
markedly, and even when adherence data are collected, this informa-
tion is rarely incorporated in the statistical analysis of major random-
ized controlled trials in Cardiology to test the consistency of the
primary endpoint(s) (see Supplementary material online, Section S1).
Based on guidance from regulators, specifically the Food and Drug
administration (FDA), adherence strategies designed to enrich clinical
trials have become a regulatory priority.9,22,23 Imprecision in assessing
and classifying non-adherence, and the lack of a consistent approach
to incorporating adherence data in the analysis of study results, may
lead to imprecision in the calculated perceived efficacy of a drug in
clinical trials. Thus many trials may not accurately answer the ques-
tion posed by the sponsors and regulators, who seek an accurate es-
timate of the true efficacy of treatment, or the question posed by
payers who seek a reliable estimate of the effectiveness of treatment
in the marketplace after approval.
For all these reasons, it is timely to consider a structured approach
to the classification, collection, and interpretation of data related to









A major challenge in correctly defining and understanding adherence
and its potential clinical implications lies in the inconsistent termin-
ology historically used throughout the medical literature (e.g. compli-
ance, persistence, concordance, etc.). However, this semantic
confusion in terminology has been largely resolved. While ‘patient
compliance’ and ‘medication adherence’ have been the most widely
used terms, each serving as indexing terms in the Index Medicus of
the US National Library of Medicine, ‘compliance’ has been increas-
ingly replaced by ‘adherence’,24 as the latter term has been thought
to evoke more the idea of cooperation between prescriber and pa-
tient, rather than passive obedience to the physician’s instructions.
The shift from ‘compliance’ to ‘adherence’ reflects a fundamental
change in understanding relationships between patients and practi-
tioners. The 2003 WHO definition of adherence—the extent to
which a person’s behaviour taking medication, following a diet, and/
or executing lifestyle changes corresponds with agreed recommen-
dations for a health care provider—has been widely adopted.10
In 2012, the Ascertaining Barriers to Compliance (ABC) project,
defined medication adherence as ‘the process by which patients take
their medication as prescribed’ while emphasizing that it encom-
passed three major components: initiation, implementation, and dis-
continuation.24 Initiation of treatment occurs when the patient takes
the first dose of the prescribed medication. Implementation is defined
as the extent to which actual behaviour corresponds to the pre-
scribed dosing regimen. Discontinuation marks the end of therapy.
The concept of ‘persistence’ is defined as the length of time between
initiation and discontinuation of treatment. Thus, optimal adherence
in the context of a clinical trial comprises initiation (a binary variable),






























































































implementation (adherence to medication based on dosing history),
and persistence until recommended discontinuation.
While medication initiation and discontinuation pose relatively
minor difficulties, the challenges derived from the complex nature of
implementation have been well documented as have the shortcom-
ings of traditional methods (mostly based on patient self-reporting or
returned pill counts) of measurement.21 The introduction of elec-
tronic monitoring combined with even more sophisticated analytic
techniques has provided a potential solution,25 the vast majority of
publications still classify patients in a dichotomous fashion based on
an 80% adherence cut-off rule derived from pill count or pharmacy
refill databases, depending on the setting. Although as a crude meas-
ure, it is associated with clinical outcomes across all therapeutic
areas,26–29 the 80% threshold should not be interpreted as a measure
of daily implementation of the dosing regimen but rather a cut point
that correlates with treatment discontinuation. More accurate meas-
ures of adherence, predominantly reflecting implementation, have
potential to enhance our understanding of its effects on outcome in
different disease states.30
Hence, a newly designed classification for non-adherence should
account for the three main elements of adherence (i.e. initiation, im-
plementation, and discontinuation), including detailed information on
dosing implementation and timing of discontinuation as well as the




Based on the aforementioned principles, the proposed four level
classification of non-adherence captures a gradient of non-
adherence, in a hierarchical fashion, from initiation through imple-
mentation to the discontinuation of treatment (Table 1 and Figure 1).
Since the clinical implications of non-adherence largely depend on
the incremental value on health-related outcomes of any investiga-
tional pharmacological treatment (i.e. lack of adherence to a toxic
drug may actually improve outcomes as compared to perfect adher-
ence), the severity of non-adherence patterns is best standardized
based on the expected degree of over- or more frequently under-
exposure to study medication for any given experimental drug.
Three additional layers of information characterize the decision-
process and circumstances underlying non-adherence, the clinical
scenario and, where relevant, the timing relative to treatment
initiation.
The gradient of adherence ranges from optimal adherence to the
study protocol (Type 0), through suboptimal treatment implementa-
tion (Type 1) to treatment discontinuation classified as temporary
(Type 2), where the period exceeds the pharmacological effect of
the study drug but treatment is recommenced, or permanent
(Type 3). Optimal adherence, classified as Type 0, allows for 5% tol-
erance, during the study timeframe, from that defined per protocol.
Incorrect implementation of the study regimen is classified as Type
1. This implies deviation from the prescribed regimen to a greater ex-
tent than the 5% tolerance allowed for optimal adherence, but with-
out fulfilling the criteria for temporary or permanent discontinuation
described below (i.e. non-consecutive, relatively sparse, and rare in-
take errors). Type 1 is further classified into three subtypes;
Type 1a—continuous exposure to a different dose of the study drug;
Type 1b—intermittent under-exposure to study drug resulting from
a decreased frequency of drug intake, resulting in total exposure
<95% of pre-specified doses; Type 1c—over-exposure owing to an
increased frequency of drug intake, resulting in total exposure
>105% of pre-specified doses. These thresholds reflect the 5% toler-
ance allowed in Type 0.
Sustained discontinuation of the study regimen for a period longer
than the pharmacological life (defined as the time from last drug in-
take to the termination of the pharmacological effect) of the drug is
classified as Type 2, if temporary, and Type 3, if permanent. The
pharmacological life is used as the discriminator to clearly distinguish
two potential scenarios. In one scenario, despite the deviations from
implementation there is still some pharmacological activity of the
study drug; in the other scenario, the deviations result in effective
temporary or permanent discontinuation of the study drug. The dur-
ation of the pharmacological life of the study drug, based on scientific
evidence, should be pre-specified in the study protocol. Examples of
pharmacological lives for out-of-hospital cardiovascular drugs are
provided in Supplementary material online, Section S3. When study
drug is permanently discontinued (Type 3) and another drug, from
the same class or a different class, is substituted, the adherence infor-
mation for the new drug is collected as described above.
The second layer classifies the decision-making process that under-
lies non-adherence. There are three subtypes: non-adherence on the
initiative of the study investigator or delegated representative (e.g.
study nurse); non-adherence on the initiative of a non-investigator
physician (e.g. general practitioner (GP) or insurance doctor) or
other health care professionals (e.g. nurse practitioners, physician
assistants, and dentists); non-adherence on the initiative of the patient
or legally deigned guardian.
The third layer, summarized in the acronym RESULT, classifies the
most common clinical scenarios underlying non-adherence, where R
stands for risk profile change, E for events, S for surgery, U for other
unlisted reasons, L for logistical issues, and T for trauma (Table 1).
The fourth layer classifies the timing of non-adherence relative to
treatment initiation. Three categories namely early, late, and very
late are proposed. The time intervals for each category should
be pre-defined by protocol. The single longest non-adherence event
(in days) and cumulative non-adherence in days should also
be reported. While the NARC classification has been developed to
capture adherence and lack thereof to study medication, the
metrics proposed below can similarly be applied to non-study drugs
(i.e. ancillary/concomitant medications recommended within the
protocol). This would allow categorization of study patients based not
only on gradients of adherence to study drug but also for pre-defined
concomitant medications which may have either major prognostic
implications or potential interaction with the study medication itself.
Principles underlying the non-adherence
classification
Gradient/pattern of non-adherence (Layer 1)
In order to account for inevitable occasional lapses by even the most

























reasonable threshold to define optimal adherence. The 5% cut-off
point to define optimal adherence is based on evidence originating
outside the cardiovascular field, where it was shown that a >5% non-
adherence pattern to thiopurines was associated to higher risk of
replaces in children affected by leukaemia.31 The majority of clinical
trials classify patients who have taken >80% of doses (generally
based on pill counts) as ‘adherent’. The choice of this threshold is
based on pharmacy refill data, which showed the best prognostic dis-
crimination with this threshold irrespective of the medication
studied.21,26–29 However, a relatively low binary threshold forces
patients with different non-adherence patterns into the same
category (Figure 2). Critically, it does not permit a distinction between
those who implement the regimen in a suboptimal fashion, while still
being continuously exposed to a potentially therapeutic concentra-
tion of the study drug from those who, with the same level of ‘adher-
ence’ based on pill counts have a different non-adherence pattern,
that includes truly off-drug time periods.
Patients whose cumulative intake of study drug is <80% are likely
to have interrupted the treatment, with loss of the pharmacological
effect, at some point during the study (Figure 3). Hence, this 20% tol-
erance seems more suitable as a prognostic rather than an adherence
marker, as it essentially captures, potentially unreported, treatment
Table 1 Non-adherence Academic Research Consortium Consensus Classification
Level 1: Captures the type of non-adherence
Type 1: Deviations from the prescribed regimen.
Intermittent variability in medication dose/exposure that does not fulfil criteria for non-adherence Types 0, 2, or 3 definitions.
a. Change in dose not pre-specified by protocol
b. Under-exposure: intake of <95% of the prescribed doses
c. Over-exposure: intake of >105% of the prescribed doses
Type 2: Temporary discontinuation
Omission of >_1 dose of prescribed medication resulting in loss of pharmacological effect, within the protocol-defined time frame, followed by resump-
tion of the prescribed regimen
Type 3: Permanent discontinuation
Permanent discontinuation of prescribed medication (resulting in loss of pharmacological effect based on a drug-specific pharmacological life within the
protocol-defined time frame).
Level 2: Captures the decision-maker responsible for non-adherence
Medically driven—investigator: change initiated by the study investigator (or delegated representative)
Medically driven—other medical professional: change initiated by another medical professional (non-investigator physician, dentist, pharmacist, etc.).
Patient driven: change initiated by the patient.
Level 3: Captures the reason(s) underlying non-adherence
Risk profile change:
Newly diagnosed/recognized medical conditions
Newly introduced/withdrawn concomitant medication
New information related to the study drug
Perception that medication not needed (patient/caregiver driven only)
Events: adverse events (anticipated or unanticipated) related to the study drug such as bleeding or ischaemic events or other drug-specific side effects
(e.g. dyspnoea, hyperkalaemia, and abnormal liver function).
Surgery:
Non-cardiac surgery (e.g. cholecystectomy and cancer surgery)
Coronary artery bypass or other cardiac surgery
Percutaneous coronary intervention
Endoscopy
Unlisted: reason not captured by the other categories such as cost of medication, lack of symptoms.
Logistic: issues related to prescription, (forgotten medication) or complexity of the pharmacotherapy (including misunderstanding of the prescribed
regimen),
Trauma: temporary or permanent discontinuation as a direct result of trauma.
Level 4: Captures the timing of non-adherence
Early: pre-defined by protocol
Late: pre-defined by protocol
Very late: pre-defined by protocol
Given the historical importance of using 80% as arbitrary cut-off point for assessing adherence or lack thereof across studies, the NARC task force favours separately
reporting this information calculated as the number of prescribed drug intakes minus the number of missed intakes divided by the number of prescribed drug intakes throughout
the study duration. Detailed examples for the practical application of the NARC classification are provided in the case-based example section and in the Supplementary material
online.












..discontinuation. In addition, a stricter adherence regimen demon-
strated a superior efficacy in studies outside the cardiovascular field,
especially for treatments with a narrow therapeutic window or a
short pharmacological half-life.31,32
Unlike previous approaches to capture and categorize adherence,
the NARC proposes a refinement based on the documented
pharmacological half-life of the study drug, in an attempt to distin-
guish non-adherence patterns which result in under- or over-
Level 1 
Captures the Type of Non-adherence 
  
Level 2 
Captures the decision-maker 
responsible for non-adherence  
Level 3 
Captures the reason(s) underlying non-
adherence 
Level 4 
Captures the timing of  
non-adherence  
R isk profile  
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Figure 1 Levels of the Non-adherence Academic Research Consortium Classification.
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C D
Figure 2 Dosing chronology plots of four patients. Calendar date (mm/dd/yy) is shown on the horizontal axis, and 24-h clock time is shown on the
vertical axis. Each blue dot indicates the electronically recorded time and date of dosing. The vertical tan lines depict missed doses, the width of which
reflects the number of days without dosing. During the depicted periods of study, each patient took 90–91% of prescribed doses, with the indicated


































..exposure to drug effect from those where patients, for variable peri-
ods, have no exposure whatsoever to a pharmacologically relevant
concentration of the study drug. Specific considerations apply for
placebo-controlled studies. As a placebo has no pharmacological life
by definition, one reasonable approach might be to arbitrarily assign a
pharmacological life to the placebo equivalent to that of the study drug.
The Type I category may pose specific challenges. In order to dis-
tinguish Type I from other categories, a highly reliable method to cap-
ture adherence pattern is required, for example electronic
monitoring. Hence, the reliability of this category within trials cannot
be disentangled from how adherence is assessed and captured during
the study conduct. Type 1A may not be applicable to blinded studies
where only one regimen of the investigational drug is assessed.
Moreover, a physician-guided change in the prescribed dose of an in-
vestigational drug should not be perceived as a non-adherence pat-
tern as long as the protocol pre-specifies the possibility to up or
down-titrate the investigational regimen based on tolerability or
other factors, such as for example concomitant medications.
Similarly, a change in drug dose in the setting of a dose finding study
where multiple investigational drug regimens are compared may be
regarded as Type 3 rather than Type 1A. Hence, the protocol should
pre-specify the applicability of Type 1A and if so clarify which drug
regimen(s) would fulfil this entity. The NARC task force suggests that
adherence be also examined on a continuous scale, as the percentage
of prescribed doses actually taken. Given the historical importance of
using 80% as arbitrary cut-off point for assessing adherence or lack
thereof across studies, the NARC task force favours separately
reporting this information calculated, over the entire study duration,
as the number of prescribed drug intakes minus the number of
missed intakes divided by the number of prescribed drug intakes
(expressed as a percentage).
Decision-making process and context underlying
non-adherence (Layers 2 and 3)
While many studies have reported the effect of treatment cessation
on subsequent cardiovascular events, few captured precisely the
Figure 3 Suboptimal implementation and evidence of temporary or permanent discontinuation. Dosing chronology plots of four patients. Days
from study inception are shown on the horizontal axis, and 24-h clock time is shown on the vertical axis. Each blue dot indicates the electronically
recorded time and date of dosing. The vertical grey lines depict missed doses, the width of which reflects the number of days without dosing. Data
from the iAdherence database.






























































































decision-making processes or the clinical scenarios that led to cessa-
tion. Treatment discontinuation may result in an adverse event or
treatment may be discontinued as a result of an adverse event.
Capturing the exact timing of adverse events and treatment discon-
tinuations generally helps in the ascertainment of the cause–effect na-
ture of this relationship; however, this may not always be possible or
reliable. The PARIS registry has shown that risk of cardiovascular
events following discontinuation of antiplatelet treatment after cor-
onary stent implantation is highly dependent on the circumstances
surrounding treatment discontinuation.33 For example, compared
with patients who remained on dual antiplatelet therapy (DAPT),
those who had physician-guided discontinuation were at significantly
lower risk of major adverse cardiovascular events compared with
those where DAPT cessation was not physician-guided.33 In the con-
text of a clinical trial, the NARC consensus was to clearly differentiate
whether physician guidance on treatment discontinuation originated
from the investigator or an authorized representative—who would
be expected to have a more in-depth knowledge about study design,
procedures, and the study drug—or from another source, including
primary a care physician or other subspecialty physicians, such as for
example gastroenterologists or dentists. The setting leading to
lack of adherence was felt to potentially be as important as the
non-adherence pattern. Outside the randomized trial setting
where costs are generally funded by the clinical investigation,
some of the decisions resulting in non-adherence may be arrived
at after discussion between the patient and his primary physician.
Where such decisions are agreed by both parties they will be clas-
sified as physician driven.
The RESULT acronym has been developed to help memorize
and easily categorize the most frequent clinical scenarios resulting
in non-adherence (Table 1). Trauma might be conceptually
included in the risk profile change category. However, based on
growing recognition of the importance of trauma as a potential
treatment modifier, especially for but not limited to antithrom-
botic drugs,33 the NARC recommends capturing it as a distinct
entity.
Timing of non-adherence (Layer 4)
The time threshold to define these categories should be pre-
specified in the protocol as the definition of a fixed time window for
different medications is not appropriate and may not be relevant for
some cardiovascular trials. In fact, the temporal impact of non-
adherence varies significantly based on the context of the study and
the indication for and/or type of medication studied (e.g. antihyper-
tensive drug vs. antiplatelet agents). Thus, the NARC proposes this





An overview of case examples for the application of the NARC classi-
fication is provided in Table 2. An additional comprehensive library of
explanatory patient case examples is provided in Supplementary ma-
terial online, Section S4.
Collecting and analysing non-
adherence
The various approaches to collect adherence information are rarely
or inconsistently incorporated in current major randomized trials
(see Supplementary material online, Section S5). Moreover, even
when adherence data are collected, they are rarely utilized in the stat-
istical analysis to test the consistency of the primary endpoint(s) (see
Supplementary material online, Section S1 and Table S1).
The imprecision introduced by the inconsistent assessment of
non-adherence in clinical trials makes estimating the efficacy of the
study drug difficult.34 Hence, clinical trials may not accurately answer
the scientific question posed by regulators, who seek an accurate es-
timate of the efficacy/method-effectiveness/causal effect (i.e. the ef-
fect if all participants were to be fully adherent) and safety of
treatment, or the question posed by payers who seek a reliable esti-
mate of the use-effectiveness (i.e. the effect with typical use) of treat-
ment in the marketplace after approval.35–39
Variability in implementing a dosage regimen can result in toxicity
or lack of effect that may differ among drugs and dose regimens (e.g.
once daily vs. twice daily) in an unpredictable fashion.17 An example,
outside the cardiovascular field, relates to human immunodeficiency
virus (HIV) pre-exposure prophylaxis with tenofovir/emtricitabine.23
While the effectiveness of tenofovir/emtricitabine in some clinical tri-
als was null,40,41 one study, which maximized adherence to the study
medication, resulted in efficacy approaching 100%.23 Based on an
adherence-adjusted analysis, the drug was subsequently approved for
its prophylactic effectiveness against infection with HIV.42
Yet, adherence data have not often been used as an explanatory
variable in registration trials as there is widespread agreement among
clinical trialists that intention-to-treat (ITT) analysis should be the pri-
mary analysis of randomized controlled trials. However, ITT ignores
the situation, now acknowledged as common, where a substantial frac-
tion of trial patients fail to take the medicine as prescribed. Supportive,
adherence-informed analysis, complementing the ITT analysis with an
appropriate adherence-adjusted analysis, would deliver:
• A robust estimate of method-effectiveness for drug efficacy when
taken correctly.
• A more accurate and cost-effective analysis of collected clinical
data (PK and PD)
• Define dosing errors that have the greatest potential to under-
mine effectiveness
• Define dosing errors that have the greatest potential to create
hazard (e.g. rebound effects after sudden cessation of dosing, re-
current first-dose effects, emergence of resistance to anti-
infective agents)
Collection of non-adherence in clinical
trials: recommendations for the case re-
port form
See Supplementary material online, Section S6.
Analysis of non-adherence in clinical tri-
als: statistical analysis considerations
The NARC classification aims to improve validity and reliability in
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Table 2 Non-adherence Academic Research Consortium Classification case examples
Definition Case examples
Level 1: Type of non-adherence event
Type 0: Complete adherence to medication as specified in
the study protocol and in any case not fulfilling criteria
for non-adherence Types 1, 2, and 3. This requires an
exposure to medication of 100 ± 5% of the doses pre-
scribed in the study protocol.a,b
Patients with pulmonary embolism, already treated with oral anticoagulants for
6 months after the event, are randomized to treatment with dabigatran or pla-
cebo for an additional period of 12 months. The primary endpoint is evaluated
after 12 months of treatment. The study protocol specifies a dose of 150 mg
twice daily for those with normal renal function reduced to 75 mg twice daily in
patients with renal impairment (creatinine clearance 15–30 mL/min).
Patient 1 has normal renal function and was treated with dabigatran 150 mg twice
daily. At follow-up, he had taken 98% of the expected doses.
Patient 2 has a creatinine clearance of 18 mL/min and was treated with dabigatran
75 mg twice daily. At follow-up, he had taken 96% of the expected doses.
Both patient fulfil NARC 0 criteria.
Type 1: Intermittent variability in medication dose/exposure
from protocol prescription not fulfilling non-adherence
Types 2 and 3 definitions.
Patients are included in an open label randomized study comparing losartan
100 mg vs. an active antihypertensive treatment. Losartan is administered once
per day. Only if systolic blood pressure at two different ambulatory measure-
ments is confirmed to be less than 100 mg, losartan 50 mg q.d. can be adminis-
tered. Follow-up visits are scheduled every 3 months. Patients are expected to
use 90 ± 4 pills between follow-up visits.
a. change in the dose specified in the protocol Patient 1 reports at a follow-up visit two episodes of mild dizziness. He felt these
episodes were related to the study medication. Systolic blood pressure meas-
urements showed values consistently above 100 mmHg. Yet, the physician
decided to down-titrate the prescribe losartan regimen to 50 mg, to avoid the
risks the patient will self-discontinue the investigational treatment. This patient
fulfils NARC Type 1a criteria.
b. under-exposure: less than 95% of the doses expected
by the protocol
Patient 2 had used 75 pills (83% of expected doses) at a follow-up visit. This pa-
tient denies having interrupted study medication at any time but reports having
forgotten some non-consecutive pills. This adherence pattern fulfils NARC
Type 1b criteria.
c. over-exposure: more than 105% of the doses expected
by the protocol
Patient 3 did not understand the physician’s instructions and took study medica-
tion twice daily for 1 week. At the follow-up visit, 97 pills have been used
(107% of expected doses). This patient has been overexposed to the study
drug fulfilling NARC Type 1c criteria.
Type 2: Temporary discontinuation of the medication caus-
ing the termination of its pharmacological effect based
on a drug-specific pharmacological life and followed by a
return to the original regimen
Patients are included in a randomized study testing ticagrelor 90 mg twice daily vs.
placebo. The pharmacological life of ticagrelor/placebo was defined in the study
protocol as 5 days. Follow-up visits are scheduled every month. Patients are
expected to use 60 ± 3 pills between follow-up visits.
Patient 1 had a nosebleed and decided to discontinue study medication until the
next follow-up visit (12 days later). At that time the investigator reinitiated study
medication. This patient discontinued study medication for longer than its
pharmacological life and fulfils NARC Type 2 criteria.
Patient 2 developed respiratory symptoms and discontinued study medication for
3 days (six doses). This patient did not discontinue study medication for longer
than the pharmacological life of the drug, but he did not implement the treat-
ment correctly as he omitted more than the tolerated three doses. This patient
fulfils NARC Type 1b criteria.
Type 3: Permanent discontinuation of the medication within
the study
Patients presenting with an acute coronary syndrome and treated with drug-elut-
ing stents are randomized to rivaroxaban 2.5 mg or placebo in addition to the
standard of care dual antiplatelet therapy regimen. The pharmacological life of
rivaroxaban/placebo was defined in the study protocol as 24 h. The primary end-
point is evaluated after 12 months of treatment.
Continued










Patient 1 was randomized to rivaroxaban 2.5 mg and after 4 months of treatment
had an intracranial bleed. Study drug was immediately discontinued and never
restarted. This patient fulfils NARC Type 3 criteria.
Patients with clinically evident atherosclerotic vascular disease
were randomized to a treatment with evolocumab 140 mg or placebo. The
pharmacological life of evolocumab/placebo was defined in the study protocol as
15 days. The primary endpoint is evaluated after 36 months of treatment.
Patient 1 was randomized to evolocumab and after 4 months of treatment had a
severe muscle pain with significant increase of creatine kinase. Study drug was
immediately discontinued and never restarted. This patient fulfils NARC Type 3
criteria.
Level 2: Decision-making process around the non-adher-
ence event
Patients presenting with an acute coronary syndrome and treated with drug-elut-
ing stents are randomized to rivaroxaban 2.5 mg or placebo in addition to the
standard of care dual antiplatelet therapy regimen. The primary endpoint is
evaluated after 12 months of treatment.
Investigator driven: change on the initiative of a study
investigator
Patient 2 was randomized to rivaroxaban 2.5 mg and after 6 months of treatment
had gastro-intestinal bleeding requiring blood transfusion. The study investiga-
tor decided to discontinue the study drug based on his clinical assessment of
the risk of further bleeding. The drug was never restarted. This patient fulfils
NARC Type 3, sub-typeIcriteria.
Other medical doctor driven: change on the initiative of any
other physician
Patient 3 was randomized to rivaroxaban 2.5 mg and after 2 months of treatment
had a scheduled hip replacement. The surgeon decided to discontinue all anti-
platelet and anticoagulant medications, including the study drug. The drug was
restarted after 20 days, at the time of the next scheduled follow-up visit. This
patient fulfils NARC Type 2, sub-type M criteria.
Patient driven: change on the initiative of the patient Patient 4 was randomized to placebo and after 8 months of treatment had a nose-
bleed. He did not contact his physician. He decided on his own initiative to dis-
continue the study drug. The drug was restarted 2 days later at the time of the
next scheduled follow-up visit. This patient fulfils NARC Type 2, sub-type P.
Level 3: Clinical scenario underlying non-adherence
Risk profile change: including but not limited to new condi-
tions or pharmacotherapy that increase patient’s risk to
receive the previously prescribed therapy.
Patients presenting with an acute coronary syndrome and treated with drug-elut-
ing stents are randomized to rivaroxaban 2.5 mg or placebo in addition to the
standard of care dual antiplatelet therapy regimen. The primary endpoint is eval-
uated after 12 months of treatment.
Patient 4 was randomized to rivaroxaban 2.5 mg and after 6 months of treatment
was diagnosed with a cerebral neoplasm. The oncologist discontinued the study
drug because of concern related to the potential risk of an intracranial bleed.
The drug was never restarted. This patient fulfils NARC Type 3, sub-type M,
sub-type R criteria.
Events: including but not limited to expected or not
expected events related to the study drug, adverse side
effect, bleeding, or ischaemic events.
Patients are included in a randomized study of ticagrelor vs. clopidogrel. Ticagrelor
(90 mg) twice daily was prescribed. Follow-up visits are scheduled every month.
Patient 4 was randomized to ticagrelor and attended his general practitioner (GP)
due to severe dyspnoea. The GP decided to discontinue ticagrelor and switch to
prasugrel. This patient fulfils NARC Type 3, sub-type M, sub-type E.
Patients are included in a randomized study of evolocumab vs. ezetimibe.
Evolocumab (140 mg) once every 2 weeks was prescribed. Follow-up visits are
scheduled 3 months. Patient 4 was randomized to evolocumab and suffered an
infection of the puncture site 1 month after study inception, which was treated
by the general practitioner. The patient skipped the following four injections and
after attending the follow-up visit decided to restart the study drug. This patient












Surgery: including but not limited to surgery, endoscopic or
other type of invasive procedures inducing drug
withdrawal
Patients are included in a randomized study of ticagrelor vs. clopidogrel. The
pharmacological life was defined in the study protocol as 5 days for ticagrelor
and 7 days for clopidogrel. Follow-up visits are scheduled every month. Patient
6 was randomized to clopidogrel and discontinued study drug for 9 consecutive
days for a planned surgical procedure on the direction of the surgeon. The
drug was then restarted. This patient fulfils NARC Type 2, sub-type M, sub-
type S criteria.
Uncertain: including all those reasons that might result in
deviation from the prescribed study drug regimen that
are not captured by the other categories of the RESULT
acronym.
A patient is included in an open label phase III study testing the efficacy/safety pro-
file of a new antiplatelet agent. The patient decided to stop the study medication
because he became convinced that the experimental drug was poison. Soon after
he was diagnosed with a psychotic illness and study drug was not restarted. This
patient fulfils NARC Type 3, sub-type P, sub-type U criteria.
Patients with symptomatic heart failure and iron deficiency are randomized to i.v.
ferric carboxymaltose or placebo once per month. The pharmacological life of
the drug was defined in the study protocol as 90 days. The primary endpoint is
evaluated after 12 months of treatment.
Patient 7 was randomized to placebo. At attending the follow-up visit the investiga-
tor noted that patient was prescribed with ciprofloxacin by the general practi-
tioner. Due to a possible drug-interaction patient was discontinued to the study
drug until the end of antibiotic treatment (skipped two doses of study drug and
then reinitiated treatment). This patient fulfils NARC Type 2, sub-type I, sub-
type U criteria.
Logistical issues: including but not limited to issues related to
prescription, cost, or complexity of the pharmacother-
apy. It may also include non-adherence due to misunder-
standing or patient forgetfulness.
Patients presenting with an acute coronary syndrome and treated with drug-elut-
ing stents are randomized to rivaroxaban 2.5 mg or placebo in addition to the
standard of care dual antiplatelet therapy regimen. The pharmacological life of
rivaroxaban/placebo was defined in the study protocol as 24 h. The primary end-
point is evaluated after 12 months of treatment.
Patient 7 was randomized to rivaroxaban 2.5 mg. The patient could not attend the
scheduled follow-up visit and ran out of study drug. As a result, the patient dis-
continued study treatment for 3 consecutive days and was then resupplied with
drug. This patient fulfils NARC Type 2, sub-type P, sub-type L criteria.
Trauma: leading to impossibility to take or concerns over
the possible increased risk of side effects of a given
treatment
Patients presenting with an acute coronary syndrome and treated with drug-elut-
ing stents are randomized to rivaroxaban 2.5 mg or placebo in addition to the
standard of care dual antiplatelet therapy regimen. The primary endpoint is eval-
uated after 12 months of treatment.
Patient 8 was randomized to placebo. After a car accident a brain computed tom-
ography (CT) scan, did not show any evidence of bleeding. However, the patient
was admitted to the intensive care unit and the intensivist together with the in-
vestigator decided to stop the study drug. The patient was discharged after
8 days and the study drug restarted. This patient fulfils NARC Type 2, sub-type I,
sub-type T criteria.
Patients with symptomatic proximal deep-vein thrombosis and active malignancy
are randomized to subcutaneous dalteparin 200 IU/Kg or oral warfarin (target
International normalized ratio (INR) 2.5). The primary endpoint is evaluated after
12 months of treatment.
Patient 8 was randomized to dalteparin. After a car accident a brain CT scan,
did not show any evidence of bleeding. However, the patient was admitted
to the intensive care unit and the intensivist together with the investigator
decided to stop the study drug. The patient was discharged after 8 days
and the study drug restarted. This patient fulfils NARC Type 2, sub-type I,
sub-type T criteria.
Continued




















..analytic efficiency. At a minimum, simply describing the overall bur-
den and different types of adherence in a uniform manner represents
an important advance from the disparate approaches commonly
used across studies. From an analytic perspective, we propose sev-
eral general guiding principles that may be followed or should be con-
sidered in clinical studies examining therapeutic pharmacologic
interventions. We suggest the following elements as important con-
siderations when designing data collection tools and analytic plans for
clinical studies with potential adherence implications (Table 3).
Statistical analyses in the setting of non-
adherence
General principles of censoring
Kaplan–Meier (KM) analyses with logrank test or Cox regression
analysis under the proportional hazards (PH) assumption is the
conventional analytic approach in randomized clinical trials with a
time-to-first-event primary endpoint, e.g. the composite of death,
myocardial infarction, or stroke. Kaplan–Meier and Cox regression




Level 4: Timing of the non-adherence eventc
Early: a deviation from prescription that occurs early after
initiation
Patients are included in a randomized study of ticagrelor vs. clopidogrel.
Ticagrelor (90 mg) twice daily was prescribed. Follow-up visits are scheduled
every month. The timing of non-adherence is defined in the protocol as fol-
lows: non-adherence occurring in the first month is defined as early; non-ad-
herence occurring after the first month but before 12 months is defined as late;
non-adherence occurring beyond 12 months is defined as very late. Patient 4
was randomized to ticagrelor and after 15 days consulted his general practitioner
with severe dyspnoea. The GP decided to discontinue ticagrelor and switch to
prasugrel. This patient fulfils NARC Type 3, sub-type M, sub-type E, timing Early
Late: a deviation from prescription that occurs late after
initiation
Patients are included in a randomized study comparing losartan 100 mg vs. placebo.
Losartan is prescribed once daily. Follow-up visits are scheduled at the first
month after randomization and every 3 months thereafter. Patients are expected
to use 90 ± 4 pills between follow-up visits. The timing of non-adherence is
defined in the protocol as follows: non-adherence occurring in the first month is
defined as early; non-adherence occurring after the first month but before
6 months is defined as late; non-adherence occurring beyond 6 months is defined
as very late.
Patient 4 was randomized to losartan 50 mg. Adherence was documented as
NARC 0 at 1-month follow-up. However, the patient misunderstood the instruc-
tions of the physician and took study medication twice daily after the first follow-
up visit for 1 week. At the second follow-up visit, at 4 months, 97 pills have been
used (107% of expected doses). This patient fulfils NARC Type 1c, sub-type P,
sub-type L, timing Late.
Very late: a deviation from prescription that occurs very
late after initiation
Patients presenting with an acute coronary syndrome and treated with drug-elut-
ing stents are randomized to rivaroxaban 2.5 mg or placebo in addition to stand-
ard of care dual antiplatelet therapy. The primary endpoint is evaluated after
12 months of treatment. The timing of non-adherence is defined in the protocol
as following: non-adherence occurring in the first month is defined as early; non-
adherence occurring after the first month but before 12 months is defined as
late; non-adherence occurring beyond 6–12 months is defined as very late.
Patient 4 was randomized to rivaroxaban 2.5 mg and after 7 months of treatment
was diagnosed with a cerebral neoplasm. The oncologist felt there was a high
bleeding risk and discontinued the study drug. The drug was never restarted.
This patient fulfils NARC Type 3, sub-type M, sub-type R, timing Very late
aIf the protocol pre-specifies a dose adjustment for specific patient categories (e.g. those with renal impairment, older age, high/low weight and so forth) a reduction/increase in
dose during the study according to protocol criteria will not be considered as non-adherence (NARC 1) but as complete adherence (NARC 0).
bIf the protocol pre-specifies a washout period, this will not be considered as a temporary drug discontinuation (NARC 2) but as complete adherence (NARC 0).
cIn studies where timing of nonadherence pattern is felt to play a crucial role (e.g. for DAPT adherence in stent studies), follow-up visits or adherence monitoring tools should
































































































no relationship whatsoever with the patient’s risk (after accounting
for characteristics in the Cox model) at the time of censoring. This
condition is met if censoring occurs at a pre-defined study termin-
ation date, e.g. 730 days after randomization of the individual patient
(i.e. a fixed duration of follow-up for all patients), or a fixed date (e.g.
365 days after randomization of the last patient), or when the primary
endpoint has occurred in a pre-specified number of patients or a pre-
specified number of events has occurred (provided the characteris-
tics of the participants when enrolled remains constant over time for
the last two scenarios). The first scenario pre-specifies a fixed dur-
ation of follow-up for all patients; the latter two involve a variable
duration of follow-up. Non-adherence or permanent discontinuation
of trial medication may frequently be related to prognosis. Therefore,
naively censoring of follow-up at the time of non-adherence or per-
manent discontinuation of trial medication without further appropri-
ate accounting for the relationship between time of non-adherence
and patient’s risk, in principle, introduces bias in a KM or Cox regres-
sion analysis. If non-adherence and then censoring occurs in patients
with a relatively poor prognosis, KM curves underestimate the event
rates over time. If non-adherence or permanent discontinuation is
asymmetrical in the two treatment groups, censoring of follow-up
typically biases the estimation of the treatment effect.
Intention-to-treat analysis
Analysis according to the ITT principle was introduced to address
the issue of (selective) withdrawal from treatment in a randomized
setting. An ITT analysis is based on two tenets. First, the outcome sta-
tus until pre-defined study termination (as defined above) is known
for all patients. Second, in the actual KM or Cox-PH analysis, events
are counted based on randomization rather than actual treatment at
the time of the event. In the presence of similar non-adherence in the
treatment arms, an ITT analysis is generally associated with a dimin-
ution of treatment differences that might have been evident if all
patients had been treated according to the study protocol. In an ITT
analysis, preservation of the comparability of the treatment groups,
as created by randomization, prevails over treatment adherence.
Since ITT is likely biased towards the null, its use for safety points is
generally discouraged. The ITT analysis assumes that an important
component of the treatment efficacy is the ability to comply with the
protocol-mandated regimen. Therefore, non-adherence is an intrin-
sic component of the overall treatment effect. In other words, an ITT
analysis does not estimate the pharmacological effect of a treatment
but a combined effect of treatment efficacy and adherence.
However, when the rate of non-adherence is high, effect estimation
by ITT could become less clinically meaningful, and the benefit of pre-
serving comparability ensured by randomization may not offset the
issues. Without supplementing ITT analysis with additional informa-
tion such as adherence rate, the interpretation of ITT result is difficult
and questionable. Furthermore, an ITT analysis pre-supposes that
follow-up and event collection is not affected by actual treatment
status.
On-treatment analysis
On-treatment (OT) analyses were introduced to accommodate that
notion that study treatments should not take into account events
that occur while the patient is off treatment. Historically, these
types of analyses have been particularly important in safety
assessments. In an OT analysis, follow-up is censored at the time
of permanent discontinuation of trial medication, which implies
that only events that occur while the patient in on the randomized
study treatment are taken into account. An OT analysis excludes
events that occurred off treatment. An OT analysis requires a
precise definition of the off-treatment period relative to the last
exposure to trial medication. Conventional choices utilize
clearance of drug concentrations in the blood or a fixed time
interval, e.g. of 28 days.
A newer variant of OT analysis allows interval censoring. This
approach introduces censoring for the duration of temporary
interruptions of trial medication. Events that occur during the
censored interval are excluded from the analysis, whereas events
that occur after resumption of treatment are again included in
the analysis.
In an OT analysis, whether with permanent or interval censoring,
censoring cannot be assumed to have occurred at random. Non-
adherent patients may be sicker and hence at higher risk for the pri-
mary outcome. In fact, it was recently shown that even non-
adherence to placebo worsens outcomes.7,43 Thus, censoring for
non-adherence (similar to any form of loss to follow-up) could lead
to biased treatment comparisons, diminishing or exaggerating the
underlying treatment effect. The direction and magnitude of the bias
is determined by the degree to which treatment withdrawal is select-
ive and its association with the risk for the primary endpoint. In an
OT analysis, adherence prevails over the preservation of the balance
of the treatment groups.
Modified intention-to-treat analysis
The term modified intention-to-treatment (mITT) analysis (or popu-
lation) is commonly used in clinical trial reports, but has no universal-
ly accepted meaning.44 Sometimes it is a variant of an OT analysis.
The term usually refers to the complete removal of non-adherent
patients (or other groups of patients) from the statistical analysis.
Post-randomization exclusions should be avoided as much as
Table 3 Principles surrounding the collection and
analysis of adherence for valid statistical analysis
• Pre-specify the definition of adherence
• Determine if adherence information will be collected in a static (at
follow-up visits only) or in a dynamic fashion (throughout the study
duration)
• Profile occurrences of medication discontinuation at a minimum by:
• Underlying reason;
• Duration;
• Pre-specify analytic plan for adherence
• Sample size/power considerations
• Must take into account primary trial hypothesis (efficacy vs.
safety)
• Pre-specify the different analytic sets, in particular the per-protocol
population






























































































possible. Justifiable exclusions comprise technical failures of the ran-
domization process, ineligible patients incorrectly randomized, and,
in double blind trials, patients who did not receive a single dose of
study drug.44 Exclusion of patients who actually started randomized
treatment should be avoided. Thus, exclusion of non-adherent
patients from the statistical analysis is strongly discouraged, even
where non-adherence commences shortly after randomization.
Per-protocol analysis
The term per-protocol analysis (or population) is also commonly
used in clinical trials reports, but, once more, has no universally
accepted meaning. The per-protocol designation sometimes
refers to the process of entry into the trial. A per-protocol ana-
lysis then implies complete removal from the analysis of patients
who violated inclusion or exclusion criteria. Quite often, a per-
protocol analysis also implies censoring of follow-up as soon as
treatment substantially deviates from the study protocol. In those
circumstances, a per-protocol analysis is similar or may even be
identical to an OT analysis.
Statistical analysis applied to the
Non-adherence Academic Research
Consortium non-adherence classification
Analyses might be performed that exclude different populations of
non-adherent patients by degree of severity, ranging from exclusion
of Type 3 non-adherence as the most stringent entity, to exclusion of
any non-adherent patients (e.g. Types 1, 2, or 3) as the most conser-
vative and inclusive formulation. Alternatively, an intermediate ap-
proach for accounting for minor types of non-adherence patterns,
(e.g. Types 1 or 2) is to exclude patients in whom more than 1 epi-
sodes of minor non-adherence pattern has occurred or further strati-
fying the patient population based on the decision-maker (e.g. Layer
2 of the classification) and/or the reason (e.g. Layer 3 of the classifica-
tion) for non-non-adherence. We in fact propose each study proto-
col to pre-specify which degree(s) and entity(ies) of non-adherence
is/are critical and factor those into the statistical analyses plan, taking
the study the type and objectives of study protocol as well as the
anticipated characteristics/effects of the study medication. Examining
the treatment effect in these different populations may be inform-
ative to not only confirm the overall results but also to assess the in-
fluence of non-adherence on the treatment effect. In this context,
pre-specifying the relevant analyses in the setting of non-adherence is
important to ensure that the observed treatment effect does not de-
viate substantially with varying levels of adherence. For example, in-
stead of claiming superiority or lack thereof of a given treatment
strategy in the various sub-populations identified by the NARC classi-
fication, heterogeneity testing should better inform the interpretation
of study results.
As discussed above, other studies may be focused on estimating
the causal effect of a treatment in the presence non-adherence itself.
In addition to a temporal dimension, the construct of adherence can
also vary in severity. As such, previous approaches quantifying adher-
ence as a binary variable (i.e. on- vs. off-treatment) at fixed follow-up
time points, do not fully represent the fluctuating nature of non-
adherent behaviour. As shown by the PARIS study, both temporal
and contextual dimensions are crucial to linking the occurrence of
non-adherence with subsequent cardiovascular risk.33 The NARC
scheme is consistent with this observation as the different levels of
non-adherence should ideally be measured at repeated time intervals
thereby allowing a natural hierarchy from less severe (Type 1) to
most severe (Type 3). The implication of this approach is shown
below in a hypothetical study where an individual’s follow-up time is
categorized into different time intervals. We assume that the trial is
designed to test the superiority of a novel drug vs. placebo in reduc-
ing risk for MI. A patient is randomized to the experimental drug,
experiences a myocardial infarction (MI) on Day 21 and then per-
manently stops the study drug on Day 31. For purposes of addressing
the question of the trial, namely whether or not the new drug is asso-
ciated with a reduction in risk for MI compared to placebo, the event
in question will be included in both the ITT and per-protocol analyses
as the event occurred while the patient was receiving protocol-
mandated study drug. However, a separate but related question is
whether or not non-adherence to the study drug increases risk for
MI. A naı̈ve analysis would categorize this patient as non-adherent
(which did occur on Day 31) and evaluate the time to MI. This ap-
proach, however, ignores the temporal link between the timing of
drug cessation and MI. Additional statistical considerations on non-
adherence in the setting of clinical trials are discussed in
Supplementary material online, Section S7.
Case-based examples for statistical
considerations on non-adherence
See Supplementary material online,Section S8.
Summary and conclusions
Patient adherence represents the crucial link between prescribed
effective medication and successful management or prevention of dis-
ease and comprises three distinct elements, initiation, implementa-
tion, and persistence. Despite the recognition that adherence is a
complex multifaceted phenomenon, many publications still classify
patients in a dichotomous fashion as ‘adherent’ or ‘non-adherent’,
and it is rarely accounted for in the statistical analysis of trials.14,21
This is generally based on an 80%29 adherence rule derived from pill
counts or pharmacy refill databases.14,26–28 Although it appears over-
ly simplistic, this dichotomous classification does have prognostic sig-
nificance. Data obtained from pharmacy refill databases show that
the 80% threshold predicts prognosis because it identifies primarily
patients who discontinue treatment. Treatment discontinuation is
highly associated with prognosis as discontinuation is often the con-
sequence of a clinical event or results in an event. However, lesser
degrees of non-adherence, short of discontinuation, have major
implications from the early phases of drug development through
the post-marketing phase. These gaps in adherence, largely undetect-
ed by the pre-electronic methods, can be the primary reason for a
failed trial (as a result of a Type 2 error), and can result in an under-
estimate of the effectiveness of a drug at doses typically administered
in Phase 2 trials leading to the selection of suboptimal, usually overes-
timated, dose regimens in Phase 3 trials. In clinical practice, unrecog-































































































invalidate assessments of therapeutic and pharmaco-economic
benefits.
In line with the original Academic Research Consortium mission,
The NARC task force has developed a series of pragmatic consensus
definitions and methodologies to classify, record, and account for
non-adherence patterns in clinical trial settings. Consistent applica-
tion of these definitions across cardiovascular clinical trials will result
in a more reliable and more efficient estimates of the efficacy and ef-
fectiveness of drugs in regulatory and post-marketing settings. While
this standardized classification and framework has been developed to
capture, classify, and report any possible degree of medication non-
adherence in clinical trials, protocol-specific adaptations based on
expected outcomes of over- or under-exposure to study medication
or depending on the pre-defined method(s) to capture adherence
patterns in a specific clinical trial is warranted. For example, it is antici-
pated that reliable collection of Type 1 non-adherence pattern will
require electronic monitoring systems to be in place during the study.
In settings where the anticipated clinical consequences of Type 1
non-adherence are considered not to be relevant for the objectives
of the study, Type 1 category may be omitted. On the other hand,
Types 2 and 3 categories by definition expose patients to off-drug
periods. As such, every effort should be made to capture these enti-
ties as here described irrespective of the availability of more sophisti-
cated monitoring systems. A proposal on how these entities may be
recorded in a standardized care report form is provided. This will still
preserve cross comparability of adherence terms among different
studies while allowing detection and characterization of more subtle
non-adherence behaviours. In the same way, capturing the timing
frame of non-adherence, as proposed in the Level 4 of the NARC
classification, might not be relevant/applicable in all clinical trial
settings.
Finally, consistent with the Academic Research Consortium
charter, this process and the definitions provided rely heavily on
consensus and integration of previously developed definitions, with
adoption and adaptation. Continuous refinement of adherence
endpoints and of their proposed categorization into a structured
hierarchical classification is envisioned as a critical step in order to
move from a consensus- to an evidence-based approach.
In conclusion, given the high prevalence of suboptimal adherence
in clinical trials combined with its deleterious clinical and societal
implications, we propose a continuous, hierarchical, and standardized
classification and framework for reporting, collecting, and analysing
medication non-adherence in clinical trials and provide a critical ap-
praisal of methodologies for adherence collection in view of the
newly proposed adherence endpoints.
Supplementary material
Supplementary material is available at European Heart Journal online.
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